Clinical trial
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic…
NCT00480571 · BioLineRx, Ltd., Industry · Completed
Key facts
| NCT number | NCT00480571 |
|---|---|
| Title | Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder |
| Official title | An Open-label, Multi-center, 6-week, Sequential Cohort Study Designed to Determine the Safety and Tolerability of Two Dose Ranges of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-affective Disorder |
| Lead sponsor | BioLineRx, Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | BL-1020, BL 1020 High Dose |
| Enrollment | 90 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 31, 2007 |
| Last update posted | Jul 21, 2009 |
| Countries | Israel, Romania |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: